Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

Gentilly,,France,,March,21,,2021:,Sign,And,Logo,On,The

Sanofi SA (NASDAQ:SNY) on Wednesday released topline data from a phase 2 study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE).

The patients had unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs), positive somatostatin analog imaging, and at least one site of measurable disease.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.